Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry
2017 (English)In: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 177, no 3, p. 449-456Article in journal (Refereed) Published
Abstract [en]
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20(+) lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N=158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44years, respectively (P=0002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P=0033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. 67%; P<000005), as did 10-year survival, 53% vs. 72% (multivariate P=0027). Although all patients were diagnosed in the 2000s, this is the longest-followed (and largest) population-based cohort. We report a hitherto unreported 15-year median age difference between sexes, increasing rituximab use and improved survival.
Place, publisher, year, edition, pages
WILEY , 2017. Vol. 177, no 3, p. 449-456
Keyword [en]
nodular lymphocyte predominant Hodgkin lymphoma, rituximab, population-based analysis, gender differences, survival
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-322680DOI: 10.1111/bjh.14567ISI: 000399957200014PubMedID: 28233899OAI: oai:DiVA.org:uu-322680DiVA, id: diva2:1099675
2017-05-292017-05-292017-05-29Bibliographically approved